Distribution Modernization Survey for Clinic and Hospital Customers

You are receiving this survey because you are involved in the care of patients receiving Hemlibra (emicizumab) and/or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information about clinic and hospital customers’ experiences to further improve the project.  This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.

The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides Canadian Blood Services with dispensing data to help us better understand how these products are being used, and ensure patients have access to the best possible care. 

Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.

The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us.